SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?


To: Scott Ozer who wrote (317)3/16/2000 10:17:00 AM
From: RWReeves  Respond to of 513
 
AVAN get Orphan Drug status from the FDA for TP-10 for use in post-op treatment for infant heart surgery . Bioworld 3/15/2000 article. Nice to have the Feds on board.

RWR